"消化器内科，内分泌・代謝内科，リウマチ・膠原病内科，呼吸器内科，循環器内科，腎臓内科，血液内科，総合診療科，脳神経内科，神経科精神科，小児科，子どものこころの診療科，放射線科，放射線治療科，皮膚科，形成外科，漢方医学科，心臓血管外科，呼吸器外科，胃腸外科，肝胆膵・移植外科，乳腺外科，小児外科，整形外科，脊椎・脊髄外科，泌尿器科，眼科，耳鼻咽喉科・頭頸部外科，産科婦人科，麻酔科蘇生科，脳神経外科，核医学診療科，歯科口腔外科，リハビリテーション科，救急科，病理診断科，がんセンター"

During the past decade, Kanazawa University Hospital conducted 88 clinical trials. In the 10-year time frame, 88 clinical trials started and 33 clinical trials were completed, i.e. on average, 37.5% percent of trials that started reached the finish line to date. In the past 5 years, 45 clinical trials started and 27 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kanazawa University Hospital" #1 sponsor was "Janssen Research & Development, LLC" with 12 trials, followed by "Pfizer" with 12 trials sponsored, "Hoffmann-La Roche" with 8 trials sponsored, "Eli Lilly and Company" with 6 trials sponsored and "Incyte Corporation" with 6 trials sponsored. Other sponsors include 60 different institutions and companies that sponsored additional 44 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kanazawa University Hospital" #1 collaborator was "Eli Lilly and Company" with 6 trials as a collaborator, "AstraZeneca" with 3 trials as a collaborator, "Merck Sharp & Dohme LLC" with 3 trials as a collaborator, "Astellas Pharma Inc" with 2 trials as a collaborator and "Japan Lung Cancer Society" with 2 trials as a collaborator. Other collaborators include 22 different institutions and companies that were collaborators in the rest 29 trials.

According to Clinical.Site data, the most researched conditions in "Kanazawa University Hospital" are "Non-Small Cell Lung Cancer" (8 trials), "Prostatic Neoplasms" (7 trials), "Multiple Myeloma" (4 trials), "Carcinoma, Hepatocellular" (3 trials) and "Carcinoma, Non-Small-Cell Lung" (3 trials). Many other conditions were trialed in "Kanazawa University Hospital" in a lesser frequency.

Most popular intervention types in "Kanazawa University Hospital" are "Drug" (94 trials), "Biological" (11 trials), "Other" (6 trials), "Device" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (30 trials), "Carboplatin" (9 trials), "Pembrolizumab" (9 trials), "Cisplatin" (8 trials) and "Dexamethasone" (7 trials). Other intervention names were less common.

The vast majority of trials in "Kanazawa University Hospital" are 95 trials for "All" genders and 12 trials for "Male" genders.

Currently, there are NaN active trials in "Kanazawa University Hospital". undefined are not yet recruiting, 22 are recruiting, 38 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 35 completed trials in Kanazawa University Hospital, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Kanazawa University Hospital, 7 "Phase 1" clinical trials were conducted, 22 "Phase 2" clinical trials and 68 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 6 trials that are defined as “Not Applicable".